The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 13, 2023
Filed:
Oct. 10, 2019
Applicant:
Stemline Therapeutics, Inc., New York, NY (US);
Inventors:
Ivan Bergstein, New York, NY (US);
Christopher Brooks, New York, NY (US);
Thomas P. Cirrito, Long Island City, NY (US);
Assignee:
Stemline Therapeutics, Inc., New York, NY (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 38/17 (2006.01); A61K 38/20 (2006.01); A61K 38/30 (2006.01); A61K 38/21 (2006.01); A61K 31/437 (2006.01); A61K 38/16 (2006.01); A61K 38/19 (2006.01); A61K 38/45 (2006.01); C07K 14/33 (2006.01); C07K 14/47 (2006.01); C07K 14/54 (2006.01); C12N 9/12 (2006.01);
U.S. Cl.
CPC ...
A61K 39/0011 (2013.01); A61K 31/437 (2013.01); A61K 38/164 (2013.01); A61K 38/1761 (2013.01); A61K 38/193 (2013.01); A61K 38/2013 (2013.01); A61K 38/2086 (2013.01); A61K 38/21 (2013.01); A61K 38/30 (2013.01); A61K 38/45 (2013.01); A61K 39/00115 (2018.08); A61K 39/001119 (2018.08); A61K 39/001122 (2018.08); C07K 14/33 (2013.01); C07K 14/4747 (2013.01); C07K 14/5437 (2013.01); C12N 9/12 (2013.01); A61K 2039/55511 (2013.01); A61K 2039/55522 (2013.01); A61K 2039/572 (2013.01); A61K 2039/80 (2018.08); C12Y 207/10001 (2013.01);
Abstract
Provided herein are cancer stem cell targeted cancer vaccines and methods for treating and vaccinating against cancer. Also contained herein are regimens by which cancer stem cell targeted cancer vaccines are administered, such regimens comprising peptides, compositions, immunomodulatory agents, and emulsifiers. Also provided are the patient populations to which the regimens are to be administered, and the dosages, schedules, route of administration for the regimens.